Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,098,316 papers from all fields of science
Search
Sign In
Create Free Account
MR 356
Known as:
MR-356
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Alprostadil
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Reversal of chloroquine resistance in murine malaria parasites by prostaglandin derivatives.
S. Chandra
,
S. Ohnishi
,
B. Dhawan
American Journal of Tropical Medicine and Hygiene
1993
Corpus ID: 22791781
An oligomeric ester of prostaglandin B2 (OC-5186) was found to reverse chloroquine resistance in the murine malarial parasite…
Expand
1993
1993
Protective effects of a prostaglandin oligomer on rats exposed to hypoxia.
T. Saito
,
I. Saito
,
T. Ohnishi
,
R. Ogawa
American Journal of Emergency Medicine
1993
Corpus ID: 27504128
1992
1992
Protective effects of a prostaglandin E1 oligomer on taurocholate‐induced rat pancreatitis
Y. Sakai
,
T. Hayakawa
,
+5 authors
S. Ohnishi
Journal of Gastroenterology and Hepatology
1992
Corpus ID: 54895
Effects of prostaglandin E (PGE) on acute pancreatitis have been controversial. This study shows the effects of PGE1 oligomer, MR…
Expand
1991
1991
[31P]MRS study of the protective effects of prostaglandin oligomers on forebrain ischemia in rats
M. Kurata
,
M. Okuda
,
M. Muneyuki
,
S. Ohnishi
Brain Research
1991
Corpus ID: 30393925
1989
1989
Prostaglandin derivatives inhibit the growth of malarial parasites in mice
S. Ohnishi
,
N. Ohnishi
,
Y. Oda
,
M. Katsuoka
Cell Biochemistry and Function
1989
Corpus ID: 32353846
New prostaglandin oligomeric derivatives, termed MR‐256 and MR‐356, were found to inhibit the growth of murine malarial parasites…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE